• 
  Françoise Revillion, Michael T. Parsons, Emma Tudini, Hongyan Li, Eric Hahnen, et al.. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40 (9), pp.1557-1578. ⟨10.1002/humu.23818⟩. ⟨hal-02194510⟩
• 
  Ingrid Masson, Laurène Larriviere, Marc-André Mahé, David Azria, Pascal Pommier, et al.. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer. Clinical and Translational Radiation Oncology, 2024, 44, pp.100702. ⟨10.1016/j.ctro.2023.100702⟩. ⟨hal-04813716⟩
• 
  Elisa Gobbini, Anne Claire Toffart, Maurice Pérol, Jean-Baptiste Assié, Michaël Duruisseaux, et al.. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2020, 21 (5), pp.e497-e510. ⟨10.1016/j.cllc.2020.04.013⟩. ⟨hal-04728622⟩
• 
  Sarah Atallah, Odile Casiraghi, Nicolas Fakhry, Michel Wassef, Emmanuelle Uro-Coste, et al.. A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. European journal of cancer, 2020, 130, pp.241-249. ⟨10.1016/j.ejca.2020.01.023⟩. ⟨hal-03599053⟩
• 
  Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
• 
  Coline Labarre, Florent Carsuzaa, Maxime Fieux, Benjamin Verillaud, Antoine Moya Plana, et al.. Interpretability of operative and pathological reports for radiotherapy planning of sinonasal carcinomas, an ancillary study of the GORTEC 2016-02 SANTAL trial. International Forum of Allergy and Rhinology, 2024, Online ahead of print. ⟨10.1002/alr.23433⟩. ⟨hal-04787514⟩
• 
  Thibaud Charrier, Nadia Haddy, Brice Fresneau, Boris Schwartz, Neige Journy, et al.. Life years lost by childhood cancer treatment and health related late effects among childhood cancer survivors. Cancer Epidemiology, 2024, 93, ⟨10.1016/j.canep.2024.102692⟩. ⟨hal-04781953⟩
• 
  Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, et al.. Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast, 2021, 57, pp.43-48. ⟨10.1016/j.breast.2021.02.014⟩. ⟨hal-04769597⟩
• 
  C.S. Groeneveld, C. Pfister, S. Culine, V. Harter, C. Krucker, et al.. Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial. Annals of Oncology, 2024, ⟨10.1016/j.annonc.2024.09.008⟩. ⟨hal-04780573⟩
• 
  Juliette Thariat, Florent Carsuzaa, Arnaud Beddok, Sophie Deneuve, Pierre-Yves Marcy, et al.. Reconstructive flap surgery in head and neck cancer patients: an interdisciplinary view of the challenges encountered by radiation oncologists in postoperative radiotherapy. Frontiers in Oncology, 2024, 14, pp.1379861. ⟨10.3389/fonc.2024.1379861⟩. ⟨hal-04564034⟩

216

209